Clinical Trials Logo

Clinical Trial Summary

The main purpose of this study was to assess the safety, tolerability, and efficacy when combining SHR-1701 and BP102 in participants with certain cancers. This study was conducted in 2 phases, Phase Ib and Phase II.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04856774
Study type Interventional
Source Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Contact Hao Shen
Phone +0518-82342973
Email [email protected]
Status Not yet recruiting
Phase Phase 1/Phase 2
Start date April 30, 2021
Completion date December 30, 2023

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03260322 - A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Phase 1
Recruiting NCT03641794 - Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers Phase 1
Active, not recruiting NCT03665129 - IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT04387916 - A Study of KC1036 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT04095273 - Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug Phase 1
Not yet recruiting NCT03692520 - Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors Phase 1
Completed NCT02997176 - An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800) Phase 1
Recruiting NCT04446260 - A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors Phase 1
Terminated NCT02253992 - An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma Phase 1/Phase 2
Completed NCT00962091 - Study of MLN8237 in Participants With Advanced Solid Tumors Phase 1
Active, not recruiting NCT04087018 - Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors Phase 1
Completed NCT03070548 - A Study of Talazoparib in Patients With Advanced Solid Tumors Phase 1
Terminated NCT02448589 - An Investigation of TAS-119 Monotherapy Phase 1
Terminated NCT01668017 - A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy Phase 1
Terminated NCT01497626 - Lapatinib and Bortezomib in Patients With Advanced Malignancies Phase 1
Recruiting NCT01226030 - Dose Escalation and PK Study of M2ES in Subjects With Advanced Solid Tumors Phase 1
Terminated NCT00932126 - This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumors Phase 1
Completed NCT01005355 - Study of IMC-1121B in Patients With Advanced Solid Tumors Phase 1
Completed NCT00827177 - Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors Phase 1
Completed NCT01471548 - Phase I Dose Escalating Study of TKI258 Phase 1